Singapore markets closed
Straits Times Index
3,332.80 -10.55 (-0.32%) Nikkei
39,583.08 +241.54 (+0.61%) Hang Seng
17,718.61 +2.14 (+0.01%) FTSE 100
8,221.26 +41.58 (+0.51%) Bitcoin USD
61,478.13 +211.12 (+0.34%) CMC Crypto 200
1,280.37 -3.46 (-0.27%)
NVO Jun 2024 149.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 11:00AM EDT. Market open.
| Previous close | 4.9900 |
| Open | 4.9900 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 149.00 |
| Expiry date | 2024-06-28 |
| Day's range | 4.9900 - 4.9900 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Yahoo FinanceWalgreens cuts EPS guidance, plans to close more stores
Walgreens is closing several stores and pulling back on VillageMD locations as it restructures the company.
ZacksNovo Nordisk (NVO) Rises Higher Than Market: Key Facts
In the closing of the recent trading day, Novo Nordisk (NVO) stood at $144.49, denoting a +0.57% change from the preceding trading day.
BenzingaNovo Nordisk Buys 2seventy's Hemophilia A Program, Divestiture Supports Exclusive Focus On Abecma
On Thursday, 2seventy Bio Inc. (NASDAQ:TSVT) completed the asset purchase agreement with Novo Nordisk A/S (NYSE:NVO). Under the terms, Novo Nordisk has acquired the Hemophilia A program and rights to 2seventy’s in vivo gene editing technology outside of oncology and gene editing for autologous or allogeneic cell therapies of immune cells for autoimmune disease. The 2seventy bio team currently involved in the program will join Novo Nordisk and continue to advance the technology. Related: FDA Appr
© 2024 Yahoo. All rights reserved.